Hematologic Cancers News

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma

Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma

Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator's choice chemotherapy of CHOP, CVP, or bendamustine.

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma

Moffitt Cancer Center investigators believe allo-HCT may actually be "curative" for patients with a certain type of lymphoma.

Rituximab in Frontline Therapy May Reduce the Risk of Transformation in Follicular Lymphoma

Rituximab in Frontline Therapy May Reduce the Risk of Transformation in Follicular Lymphoma

The introduction of rituximab has greatly improved outcomes among patients with follicular lymphoma, but its impact on the risk of transformation and post-transformation are unclear.

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.

Ibrutinib May Be Effective as First-Line Agent in Treatment of Waldenström's Macroglobulinemia

Ibrutinib May Be Effective as First-Line Agent in Treatment of Waldenström's Macroglobulinemia

The effectiveness of ibrutinib in the frontline setting has not been definitively established.

Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia

Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia

The efficacy of rituximab plus prednisolone had not been evaluated prior to the current study.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenström Macroglobulinemia

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenström Macroglobulinemia

Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs